Protein Kinase Inhibitors: all 15,766 studies that test it

Page 18 of 158. Open to participants first (2,605), then studies with results posted, then the rest; newest registration first within each.

• Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic CancerRecruitingNCT06051851Phase 2
• A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)RecruitingNCT06051409Phase 3
• A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological MalignanciesRecruitingNCT06049667Phase 1
• The Effects of Ripasudil in Patients with FED Undergoing Femtosecond Laser Assisted Cataract SurgeryRecruitingNCT06048380Phase 3
• A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung CancerRecruitingNCT06046495Phase 1
• Effectiveness of Tofacitinib in Systemic SclerosisRecruitingNCT06044844Phase 2
• Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal AdenocarcinomaRecruitingNCT06044311Phase 2
• Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung CanceRecruitingNCT06043973Phase 3
• Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's TransformationRecruitingNCT06043674Phase 2
• A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid TumorsRecruitingNCT06037317Phase 1
• Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast CancerRecruitingNCT06035679Not applicable
• A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsRecruitingNCT06034002Phase 1
• Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICCNot yet recruitingNCT06033118Phase 1/2
• Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11)RecruitingNCT06032845Phase 2
• Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant TreatmentNot yet recruitingNCT06032728Not applicable
• Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint InhibitorsNot yet recruitingNCT06031480Phase 2
• IN10018 Combination Therapy in Treatment-naïve ES-SCLCRecruitingNCT06030258Phase 1/2
• Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR MutationsNot yet recruitingNCT06029816Phase 2
• Zanubrutinib and Tafasitamab in Mantle Cell LymphomaRecruitingNCT06029309Phase 1/2
• Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC PatientsNot yet recruitingNCT06028633Phase 2
• KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsRecruitingNCT06026410Phase 1
• A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for LiposarcomasRecruitingNCT06025747Phase 1
• Targeting Endoplasmic Reticulum Stress in Human HypertensionRecruitingNCT06025630Phase 1/2
• Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid TumorsRecruitingNCT06022289Phase 2
• Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid LeukemiaRecruitingNCT06022003Phase 2
• The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic AnemiaRecruitingNCT06021977Phase 2
• Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib MonotherapyNot yet recruitingNCT06020989Phase 2
• The Efficacy and Safety of KN046 Combined With AxitinibRecruitingNCT06020352Phase 2/3
• Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II StudyRecruitingNCT06018714Phase 2
• Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility StudyRecruitingNCT06016387Phase 2
• IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian CancerRecruitingNCT06014528Phase 2
• A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia AreataRecruitingNCT06012240Phase 3
• Tofacitinib Associated With Meglumine Antimoniate in Cutaneous LeishmaniasisNot yet recruitingNCT06011343Phase 2/3
• A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.RecruitingNCT06010901Phase 1
• Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRCRecruitingNCT06010888Phase 2
• A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors PatientsRecruitingNCT06010342Phase 2
• A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLCRecruitingNCT06010329Phase 2
• Neratinib in Combination With Ruxolitinib in Patients With mTNBCRecruitingNCT06008275Early Phase 1
• Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal CancerRecruitingNCT06008119Phase 3
• Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant MelanomaRecruitingNCT06008106Phase 3
• A Study of Avutometinib and Defactinib in People With Thyroid CancerRecruitingNCT06007924Phase 2
• Effect of Hebal and Synthetic Medicamentss on Enterococcus FeacalisNot yet recruitingNCT06006663Phase 2/3
• Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune ThrombocytopeniaRecruitingNCT06004856Phase 3
• Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast CancerNot yet recruitingNCT06000033Phase 2
• A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With CancerRecruitingNCT05999994Phase 2
• A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)RecruitingNCT05999149Phase 3
• Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS LymphomaRecruitingNCT05998642Phase 2
• To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCHRecruitingNCT05997602Phase 2
• A Single Arm, Phase II Exploratory Clinical Study of Pemitinib in Advanced Gastric Cancer With Previous Standard Therapy Failure the FGFR VariantNot yet recruitingNCT05997459Phase 2
• Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial CancerRecruitingNCT05997017Phase 2
• Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host DiseaseRecruitingNCT05996627Phase 2
• Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal CarcinomaNot yet recruitingNCT05996484Phase 2
• Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung CancerNot yet recruitingNCT05994339Phase 2/3
• IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLCRecruitingNCT05994131Phase 1/2
• LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell MalignanciesRecruitingNCT05990465Phase 1
• A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)RecruitingNCT05989542Phase 3
• Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid CancerRecruitingNCT05989425Phase 2
• Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLCRecruitingNCT05987826Phase 2
• I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast CancersNot yet recruitingNCT05986071Phase 1/2
• Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed TherapyRecruitingNCT05985954Phase 1
• KN 046 Plus Regorafenib in MSS Metastatic Colorectal CancerRecruitingNCT05985109Phase 2
• A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients with Advanced or Metastatic Solid TumorsRecruitingNCT05983523Phase 1
• A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular MalformationsRecruitingNCT05983159Phase 2
• Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast CancerRecruitingNCT05983107Phase 2
• A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's MacroglobulinemiaRecruitingNCT05979948Phase 2
• Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)RecruitingNCT05976997Phase 2
• The Effects of an Anti-inflammatory Diet With or Without Curcumin Supplementation on Anthropometric Measurements, Concentrations of Thyroid Hormones, Anti-TPO, and Systemic Inflammation in Plasma and NFK-B in Peripheral Blood Mononuclear Cells in Patients With HashimatoNot yet recruitingNCT05975866Not applicable
• Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing DiseaseRecruitingNCT05971758Phase 2
• Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular CarcinomaRecruitingNCT05971199Phase 2
• Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GISTNot yet recruitingNCT05970900Phase 3
• Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor ThrombusRecruitingNCT05969496Phase 2
• A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic CancerRecruitingNCT05969171Phase 2
• Role of Curcumin in Paclitaxel Induced PNNot yet recruitingNCT05966441Phase 2
• Go-CHOP as the Frontline Therapy for PTCLRecruitingNCT05963347Phase 2
• Effect of JAK Inhibitor on Erosion Healing in RARecruitingNCT05955066Phase 4
• Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) SubtypeRecruitingNCT05954442Phase 3
• A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 StudyRecruitingNCT05954429Phase 2
• Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic SarcomaRecruitingNCT05952128Phase 2
• Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCLRecruitingNCT05952024Phase 2
• A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLLRecruitingNCT05950997Not applicable
• Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial CancerRecruitingNCT05950464Phase 1
• Rapalog Pharmacology (RAP PAC) StudyRecruitingNCT05949658Phase 1
• Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast CancerRecruitingNCT05949541Phase 2
• OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older AdultsNot yet recruitingNCT05949424Phase 4
• Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.RecruitingNCT05948943Phase 2/3
• TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain MetastasesRecruitingNCT05948813Phase 2
• A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).RecruitingNCT05947851Phase 3
• Concomitant Curcumin Palliative Radiotherapy in Advanced Cervical Cancer TrialRecruitingNCT05947513Not applicable
• Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.RecruitingNCT05946460Phase 2
• Bioequivalence Studies of Dasatinib 100 MgNot yet recruitingNCT05944783Phase 4
• A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.RecruitingNCT05944224Phase 1/2
• Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaRecruitingNCT05943496Phase 1
• A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and ChemotherapyRecruitingNCT05942508Phase 1
• Abemaciclib in Newly Diagnosed Meningioma PatientsRecruitingNCT05940493Phase 2
• Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT05940051Phase 2
• A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)RecruitingNCT05934513Phase 1/2
• A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell LymphomaRecruitingNCT05933967Phase 2
• Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 InhibitorRecruitingNCT05933395Phase 2
• Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune ThrombocytopeniaRecruitingNCT05932524Phase 2
• Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung CancerNot yet recruitingNCT05932264Phase 2

← Protein Kinase Inhibitors overview